MARKET

EYEG

EYEG

EyeGate Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.18
+0.14
+2.78%
Closed 16:00 07/14 EDT
OPEN
5.10
PREV CLOSE
5.04
HIGH
5.20
LOW
4.829
VOLUME
26.27K
TURNOVER
--
52 WEEK HIGH
12.89
52 WEEK LOW
2.250
MARKET CAP
23.97M
P/E (TTM)
-1.7710
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EYEG stock price target is 90.00 with a high estimate of 90.00 and a low estimate of 90.00.

EPS

EYEG News

More
EyeGate Pharma to proceed its lead product pivotal study in dry eye disease
The FDA has signed off on filing of an Investigational Device Exemption (IDE) application to commence pivotal study of EyeGate Pharmaceuticals's (EYEG -1.6
seekingalpha · 12h ago
EyeGate Pharma To Proceed With PE Pivotal Study
WALTHAM, MA / ACCESSWIRE / July 14, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of
Benzinga · 21h ago
Eyegate Pharmaceuticals shares are trading higher after the company announced it has received positive feedback from the FDA regarding its Ocular Bandage Gel packaging.
Benzinga · 06/11 13:44
EyeGate Pharma Receives Positive Feedback from FDA Regarding Ocular Bandage Gel Packaging
Benzinga · 06/11 10:56
EYEG: Solid results moving towards regulatory filings later this year
Zacks Small Cap Research · 05/19 14:11
HC Wainwright & Co. Reiterates Buy on Eyegate Pharmaceuticals, Announces $12 Price Target
HC Wainwright & Co. reiterates Eyegate Pharmaceuticals (NASDAQ:EYEG) with a Buy and announces $12 price target.
Benzinga · 05/19 11:10
EYEG: An Active 2020 with More to Come
Zacks Small Cap Research · 05/06 14:10
Company News for Apr 1, 2020
Zacks · 04/01 14:04

Industry

Pharmaceuticals
+1.34%
Pharmaceuticals & Medical Research
+1.70%

Hot Stocks

Symbol
Price
%Change

About EYEG

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
More

Webull offers kinds of Eyegate Pharmaceuticals Inc stock information, including NASDAQ:EYEG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYEG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EYEG stock methods without spending real money on the virtual paper trading platform.